ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Ligand Pharmaceuticals Incorporated (LGND) Report Updated: Oct 19, 2014 | Print This Page

Ligand Pharmaceuticals Incorporated© quotemedia

Company Profile

Ligand Pharmaceuticals Incorporated operates as a biotechnology company. It principally engages in the development and acquisition of royalty revenue generating assets. The company engages in the research, milestone, and royalty revenue activities resulting from its collaborations with pharmaceutical partners. The collaborations primarily include ongoing clinical programs at Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Merck & Co., Cephalon, Inc, and Celgene. These partnered product candidates are being studied for the treatment of indications, such as thrombocytopenia, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, osteoporosis, menopausal symptoms, and Alzheimer’s disease. Ligand Pharmaceuticals Incorporated receives royalties principally on sales of Avinza from Pfizer, Promacta from GlaxoSmithKline, and Viviant /Conbriza from Pfizer. The company through its subsidiary, CyDex Pharmaceuticals, Inc., offers four marketed products, as well as has one approved product, a portfolio of partnered drug development programs, an internal pipeline of proprietary drugs, and the Captisol drug formulation platform technology. Ligand Pharmaceuticals Incorporated was formerly known as Progenx Inc. and changed its name in 1989. The company was founded in 1987 and is based in La Jolla, California.

Recent News: Ligand Pharmaceuticals Incorporated